But researchers are enamored with the pointy-face shrew for another one of its natural talents: It vomits. That makes the ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

Linda Bethea details how the marketer of brands including Oikos and Silk is approaching emerging channels and artificial ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Patients with diabetes taking a semaglutide medication face a higher risk of NAION, a potentially debilitating ophthalmic condition. Semaglutide medication use is linked with a greater risk of ...

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.